Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies.

Peric Z, Mohty R, Bastos J, Brissot E, Battipaglia G, Belhocine R, Sestili S, Giannotti F, Vekhoff A, Ledraa T, Legrand O, Lapusan S, Isnard F, Labopin M, Bonnin A, Mediavilla C, Rubio MT, Ruggeri A, Duléry R, Malard F, Mohty M.

Bone Marrow Transplant. 2019 Oct 31. doi: 10.1038/s41409-019-0726-7. [Epub ahead of print]

PMID:
31673080
2.

Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia.

Debureaux PE, Labopin M, Mamez AC, Lapusan S, Isnard F, Adaeva R, Bonnin A, Hirsch P, Delhommeau F, Battipaglia G, Duléry R, Malard F, Vekhoff A, Mohty M, Legrand O, Brissot E.

Bone Marrow Transplant. 2019 Sep 25. doi: 10.1038/s41409-019-0690-2. [Epub ahead of print]

PMID:
31554931
3.

Infectious complications after post-transplantation cyclophosphamide and anti-thymocyte globulin-based haploidentical stem cell transplantation.

Mohty R, Brissot E, Battipaglia G, Ruggeri A, Dulery R, Bonnin A, Médiavilla C, Sestili S, Belhocine R, Vekhoff A, Ledraa T, Lapusan CS, Adaeva R, Isnard F, Legrand O, Mohty M, Malard F.

Br J Haematol. 2019 Nov;187(3):e64-e68. doi: 10.1111/bjh.16189. Epub 2019 Sep 5. No abstract available.

PMID:
31487392
4.

Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update.

Battipaglia G, Massoud R, Ahmed SO, Legrand O, El Cheikh J, Youniss R, Aljurf M, Mohty M, Bazarbachi A.

Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):506-508. doi: 10.1016/j.clml.2019.04.004. Epub 2019 Apr 18.

PMID:
31122828
5.

Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation.

Duléry R, Bastos J, Paviglianiti A, Malard F, Brissot E, Battipaglia G, Médiavilla C, Giannotti F, Banet A, de Wyngaert ZV, Ledraa T, Belhocine R, Sestili S, Adaeva R, Lapusan S, Isnard F, Legrand O, Vekhoff A, Rubio MT, Ruggeri A, Mohty M.

Biol Blood Marrow Transplant. 2019 Jul;25(7):1407-1415. doi: 10.1016/j.bbmt.2019.02.025. Epub 2019 Mar 11.

PMID:
30871978
6.

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial.

Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Caillot D, Legrand O, Thomas X, Gardin C, Gogat-Marchant K, Rubin SD, Benner RJ, Bousset P, Preudhomme C, Chevret S, Dombret H, Castaigne S.

Haematologica. 2019 Jan;104(1):113-119. doi: 10.3324/haematol.2018.188888. Epub 2018 Aug 3.

7.

Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study.

Picod A, Bonnin A, Battipaglia G, Giannotti F, Ruggeri A, Brissot E, Malard F, Médiavilla C, Belhocine R, Vekhoff A, Gueye MS, Lapusan S, Adaeva R, Isnard F, Legrand O, Baylatry MT, Joly AC, Labopin M, Duléry R, Mohty M.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1471-1475. doi: 10.1016/j.bbmt.2018.02.015. Epub 2018 Mar 1.

8.

Fluctuations in an established transmission in the presence of a complex environment.

Savin DV, Richter M, Kuhl U, Legrand O, Mortessagne F.

Phys Rev E. 2017 Sep;96(3-1):032221. doi: 10.1103/PhysRevE.96.032221. Epub 2017 Sep 20.

PMID:
29346952
9.

Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors.

Duléry R, Ménard AL, Chantepie S, El-Cheikh J, François S, Delage J, Giannotti F, Ruggeri A, Brissot E, Battipaglia G, Malard F, Belhocine R, Sestili S, Vekhoff A, Delhommeau F, Reman O, Legrand O, Labopin M, Rubio MT, Mohty M.

Biol Blood Marrow Transplant. 2018 May;24(5):1013-1021. doi: 10.1016/j.bbmt.2018.01.005. Epub 2018 Jan 11.

10.

Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143).

Zhang Y, Saavedra E, Tang R, Gu Y, Lappin P, Trajkovic D, Liu SH, Smeal T, Fantin V, De Botton S, Legrand O, Delhommeau F, Pernasetti F, Louache F.

Sci Rep. 2017 Aug 4;7(1):7305. doi: 10.1038/s41598-017-07848-8.

11.

Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.

Battipaglia G, Ruggeri A, Massoud R, El Cheikh J, Jestin M, Antar A, Ahmed SO, Rasheed W, Shaheen M, Belhocine R, Brissot E, Dulery R, Eder S, Giannotti F, Isnard F, Lapusan S, Rubio MT, Vekhoff A, Aljurf M, Legrand O, Mohty M, Bazarbachi A.

Cancer. 2017 Aug 1;123(15):2867-2874. doi: 10.1002/cncr.30680. Epub 2017 Apr 7.

12.

Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia.

Hirsch P, Tang R, Abermil N, Flandrin P, Moatti H, Favale F, Suner L, Lorre F, Marzac C, Fava F, Mamez AC, Lapusan S, Isnard F, Mohty M, Legrand O, Douay L, Bilhou-Nabera C, Delhommeau F.

Haematologica. 2017 Jul;102(7):1227-1237. doi: 10.3324/haematol.2016.159681. Epub 2017 Mar 16.

13.

Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia.

Hirsch P, Zhang Y, Tang R, Joulin V, Boutroux H, Pronier E, Moatti H, Flandrin P, Marzac C, Bories D, Fava F, Mokrani H, Betems A, Lorre F, Favier R, Féger F, Mohty M, Douay L, Legrand O, Bilhou-Nabera C, Louache F, Delhommeau F.

Nat Commun. 2016 Aug 18;7:12475. doi: 10.1038/ncomms12475.

14.

Trichosporon: another yeast-like organism responsible for immune reconstitution inflammatory syndrome in patients with hematological malignancy.

Alby-Laurent F, Dollfus C, Ait-Oufella H, Rambaud J, Legrand O, Tabone MD, Hennequin C.

Hematol Oncol. 2017 Dec;35(4):900-904. doi: 10.1002/hon.2309. Epub 2016 Jun 15.

PMID:
27301878
15.

Lossy chaotic electromagnetic reverberation chambers: Universal statistical behavior of the vectorial field.

Gros JB, Kuhl U, Legrand O, Mortessagne F.

Phys Rev E. 2016 Mar;93(3):032108. doi: 10.1103/PhysRevE.93.032108. Epub 2016 Mar 7.

PMID:
27078293
16.

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.

Olombel G, Guerin E, Guy J, Perrot JY, Dumezy F, de Labarthe A, Bastie JN, Legrand O, Raffoux E, Plesa A, Wagner-Ballon O, Cornet E, Salaun V, Preudhomme C, Thomas X, Pautas C, Chantepie S, Turlure P, Castaigne S, Dombret H, Feuillard J.

Blood. 2016 Apr 28;127(17):2157-60. doi: 10.1182/blood-2016-01-689976. Epub 2016 Feb 29. No abstract available.

PMID:
26929274
17.

Clonal history of a cord blood donor cell leukemia with prenatal somatic JAK2 V617F mutation.

Hirsch P, Mamez AC, Belhocine R, Lapusan S, Tang R, Suner L, Bories D, Marzac C, Fava F, Legrand O, Mohty M, Douay L, Delhommeau F.

Leukemia. 2016 Aug;30(8):1756-9. doi: 10.1038/leu.2016.31. Epub 2016 Mar 1. No abstract available.

PMID:
26876594
18.

The CNGRC-GG-D(KLAKLAK)2 peptide induces a caspase-independent, Ca2+-dependent death in human leukemic myeloid cells by targeting surface aminopeptidase N/CD13.

Bouchet S, Tang R, Fava F, Legrand O, Bauvois B.

Oncotarget. 2016 Apr 12;7(15):19445-67. doi: 10.18632/oncotarget.6523.

19.

Incidence and risk factors for hemorrhagic cystitis in unmanipulated haploidentical transplant recipients.

Ruggeri A, Roth-Guepin G, Battipaglia G, Mamez AC, Malard F, Gomez A, Brissot E, Belhocine R, Vekhoff A, Lapusan S, Isnard F, Legrand O, Gozlan J, Boutolleau D, Ledraa T, Labopin M, Rubio MT, Mohty M.

Transpl Infect Dis. 2015 Dec;17(6):822-30. doi: 10.1111/tid.12455. Epub 2015 Nov 25.

PMID:
26354178
20.

A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study.

Hunault-Berger M, Leguay T, Huguet F, Leprêtre S, Deconinck E, Ojeda-Uribe M, Bonmati C, Escoffre-Barbe M, Bories P, Himberlin C, Chevallier P, Rousselot P, Reman O, Boulland ML, Lissandre S, Turlure P, Bouscary D, Sanhes L, Legrand O, Lafage-Pochitaloff M, Béné MC, Liens D, Godfrin Y, Ifrah N, Dombret H; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL).

Am J Hematol. 2015 Sep;90(9):811-8. doi: 10.1002/ajh.24093.

21.

Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells.

El Hajj H, Dassouki Z, Berthier C, Raffoux E, Ades L, Legrand O, Hleihel R, Sahin U, Tawil N, Salameh A, Zibara K, Darwiche N, Mohty M, Dombret H, Fenaux P, de Thé H, Bazarbachi A.

Blood. 2015 May 28;125(22):3447-54. doi: 10.1182/blood-2014-11-612416. Epub 2015 Mar 23.

PMID:
25800051
22.

Experimental Width Shift Distribution: A Test of Nonorthogonality for Local and Global Perturbations.

Gros JB, Kuhl U, Legrand O, Mortessagne F, Richalot E, Savin DV.

Phys Rev Lett. 2014 Nov 28;113(22):224101. Epub 2014 Nov 26.

PMID:
25494073
23.

Prognosis of body mass index and chemotherapy dose capping in acute myeloid leukaemia.

Kempf E, Hirsch P, Labopin M, Viguié F, Isnard F, Tang R, Marzac C, Marie JP, Mohty M, Legrand O.

Leuk Res. 2014 Dec;38(12):1425-9. doi: 10.1016/j.leukres.2014.09.013. Epub 2014 Oct 7.

PMID:
25443887
24.

Targeting CD13 (aminopeptidase-N) in turn downregulates ADAM17 by internalization in acute myeloid leukaemia cells.

Bouchet S, Tang R, Fava F, Legrand O, Bauvois B.

Oncotarget. 2014 Sep 30;5(18):8211-22.

25.

Report of disseminated Mycobacterium haemophilum infection after double cord blood allo-SCT.

Brissot E, Gomez A, Aline-Fardin A, Lalande V, Lapusan S, Isnard F, Legrand O, Meynard JL, Rubio MT, Mohty M.

Bone Marrow Transplant. 2014 Oct;49(10):1347-8. doi: 10.1038/bmt.2014.144. Epub 2014 Jul 14. No abstract available.

PMID:
25029233
26.

Interest of cytogenetic and FISH evaluation for prognosis evaluation in 198 patients with acute myeloid leukemia in first complete remission in a single institution.

Hirsch P, Labopin M, Viguié F, Perot C, Isnard F, Mamez AC, Bilhou-Nabera C, Marzac C, Delhommeau F, Lapusan S, Marie JP, Mohty M, Legrand O.

Leuk Res. 2014 Aug;38(8):907-12. doi: 10.1016/j.leukres.2014.05.021. Epub 2014 Jun 4.

PMID:
24957411
27.

Acute myeloid leukemia in patients older than 75: prognostic impact of FLT3-ITD and NPM1 mutations.

Hirsch P, Qassa G, Marzac C, Tang R, Perrot JY, Isnard F, Mohty M, Marie JP, Legrand O.

Leuk Lymphoma. 2015 Jan;56(1):147-50. doi: 10.3109/10428194.2014.913288. Epub 2014 Jun 16.

PMID:
24724782
28.

Long-term imatinib maintenance therapy for adult Philadelphia positive acute lymphoblastic leukemia.

Guillet S, Hirsch P, Marzac C, Mohty M, Marie JP, Legrand O.

Leuk Lymphoma. 2014 Nov;55(11):2646-8. doi: 10.3109/10428194.2014.889828. Epub 2014 Mar 10. No abstract available.

PMID:
24491028
29.

Beware of hidden trains: simultaneous discovery of a MYH9-related disease and chronic lymphocytic leukaemia.

Chaquin M, Marzac C, Legrand O, Favier R.

Br J Haematol. 2014 Jan;164(2):162. doi: 10.1111/bjh.12583. Epub 2013 Oct 10. No abstract available.

PMID:
24117195
30.

Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study.

Gorin NC, Isnard F, Garderet L, Ikhlef S, Corm S, Quesnel B, Legrand O, Cachanado M, Rousseau A, Laporte JP.

Eur J Haematol. 2013 Oct;91(4):315-21. doi: 10.1111/ejh.12154. Epub 2013 Aug 28.

PMID:
23738686
31.

[Macrophage activation syndrome as the presenting manifestation of intravascular lymphoma].

Oehler E, Soubiran G, Fabiani B, Legrand O, Rio B, Ghawche F.

Rev Med Interne. 2013 Oct;34(10):636-40. doi: 10.1016/j.revmed.2012.10.001. Epub 2013 May 6. French.

PMID:
23660185
32.

Experimental phase-space-based optical amplification of scar modes.

Michel C, Tascu S, Doya V, Aschiéri P, Blanc W, Legrand O, Mortessagne F.

Phys Rev E Stat Nonlin Soft Matter Phys. 2012 Apr;85(4 Pt 2):047201. Epub 2012 Apr 18.

PMID:
22680605
33.

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, Marolleau JP, Aljijakli A, Rousselot P, Fenaux P, Preudhomme C, Chevret S, Dombret H; Acute Leukemia French Association.

Lancet. 2012 Apr 21;379(9825):1508-16. doi: 10.1016/S0140-6736(12)60485-1. Epub 2012 Apr 5. Erratum in: Lancet. 2018 Feb 8;:.

PMID:
22482940
34.

Double-delayed intensification paediatric protocol without radiotherapy is an efficient treatment in adult lymphoblastic lymphoma.

Corre E, Marjanovic Z, Lapusan S, Vekhoff A, Hirsch P, Marie JP, Legrand O.

Hematol Oncol. 2012 Dec;30(4):206-9. doi: 10.1002/hon.2007. Epub 2012 Jan 23.

PMID:
22271176
35.

Prognostic impact of high ABC transporter activity in 111 adult acute myeloid leukemia patients with normal cytogenetics when compared to FLT3, NPM1, CEBPA and BAALC.

Hirsch P, Tang R, Marzac C, Perrot JY, Fava F, Bernard C, Jeziorowska D, Marie JP, Legrand O.

Haematologica. 2012 Feb;97(2):241-5. doi: 10.3324/haematol.2010.034447. Epub 2011 Nov 4.

36.

ATP Binding Cassette transporters associated with chemoresistance: transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of 281 acute myeloid leukemia patients.

Marzac C, Garrido E, Tang R, Fava F, Hirsch P, De Benedictis C, Corre E, Lapusan S, Lallemand JY, Marie JP, Jacquet E, Legrand O.

Haematologica. 2011 Sep;96(9):1293-301. doi: 10.3324/haematol.2010.031823. Epub 2011 May 23.

37.

Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia.

Lapusan S, Vidriales MB, Thomas X, de Botton S, Vekhoff A, Tang R, Dumontet C, Morariu-Zamfir R, Lambert JM, Ozoux ML, Poncelet P, San Miguel JF, Legrand O, DeAngelo DJ, Giles FJ, Marie JP.

Invest New Drugs. 2012 Jun;30(3):1121-31. doi: 10.1007/s10637-011-9670-0. Epub 2011 Apr 26.

PMID:
21519855
38.

Statistics of resonance states in a weakly open chaotic cavity with continuously distributed losses.

Poli C, Legrand O, Mortessagne F.

Phys Rev E Stat Nonlin Soft Matter Phys. 2010 Nov;82(5 Pt 2):055201. Epub 2010 Nov 3.

PMID:
21230535
39.

A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study.

Hunault-Berger M, Leguay T, Thomas X, Legrand O, Huguet F, Bonmati C, Escoffre-Barbe M, Legros L, Turlure P, Chevallier P, Larosa F, Garban F, Reman O, Rousselot P, Dhédin N, Delannoy A, Lafage-Pochitaloff M, Béné MC, Ifrah N, Dombret H; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL).

Haematologica. 2011 Feb;96(2):245-52. doi: 10.3324/haematol.2010.027862. Epub 2010 Oct 22.

40.

Outcome of 40 adults aged from 18 to 55 years with acute lymphoblastic leukemia treated with double-delayed intensification pediatric protocol.

Haïat S, Marjanovic Z, Lapusan S, Vekhoff A, Rio B, Corre E, Dimicoli S, Hirsch P, Marie JP, Legrand O.

Leuk Res. 2011 Jan;35(1):66-72. doi: 10.1016/j.leukres.2010.04.002.

PMID:
20434771
41.

Statistics of resonance states in open chaotic systems: a perturbative approach.

Poli C, Savin DV, Legrand O, Mortessagne F.

Phys Rev E Stat Nonlin Soft Matter Phys. 2009 Oct;80(4 Pt 2):046203. Epub 2009 Oct 5.

PMID:
19905411
42.

Avoided-level-crossing statistics in open chaotic billiards.

Poli C, Dietz B, Legrand O, Mortessagne F, Richter A.

Phys Rev E Stat Nonlin Soft Matter Phys. 2009 Sep;80(3 Pt 2):035204. Epub 2009 Sep 25.

PMID:
19905168
43.

Quasimodes of a chaotic elastic cavity with increasing local losses.

Xeridat O, Poli C, Legrand O, Mortessagne F, Sebbah P.

Phys Rev E Stat Nonlin Soft Matter Phys. 2009 Sep;80(3 Pt 2):035201. Epub 2009 Sep 4.

PMID:
19905165
44.

Controlled excitation of scar modes in passive and active multimode chaotic fiber.

Michel C, Doya V, Tascu S, Blanc W, Legrand O, Mortessagne F.

Appl Opt. 2009 Nov 1;48(31):G163-8. doi: 10.1364/AO.48.00G163.

PMID:
19881639
45.

High Id1 expression is associated with poor prognosis in 237 patients with acute myeloid leukemia.

Tang R, Hirsch P, Fava F, Lapusan S, Marzac C, Teyssandier I, Pardo J, Marie JP, Legrand O.

Blood. 2009 Oct 1;114(14):2993-3000. doi: 10.1182/blood-2009-05-223115. Epub 2009 Jul 30.

PMID:
19643984
46.

P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients.

Tang R, Cohen S, Perrot JY, Faussat AM, Zuany-Amorim C, Marjanovic Z, Morjani H, Fava F, Corre E, Legrand O, Marie JP.

BMC Cancer. 2009 Jun 23;9:199. doi: 10.1186/1471-2407-9-199.

48.

When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group).

Cassinat B, de Botton S, Kelaidi C, Ades L, Zassadowski F, Guillemot I, Schlageter MH, Raffoux E, Harousseau JL, Legrand O, Escoffre-Barbe M, Reman O, Gardembas M, Himberlin C, Cahn JY, Guyotat D, Bouscary D, Parry A, Rousselot P, Baruchel A, Dombret H, Chevret S, Fenaux P, Chomienne C.

Leuk Res. 2009 Sep;33(9):1178-82. doi: 10.1016/j.leukres.2008.12.010. Epub 2009 Jan 23.

PMID:
19167754
49.

Is BAL useful in patients with acute myeloid leukemia admitted in ICU for severe respiratory complications?

Rabbat A, Chaoui D, Lefebvre A, Roche N, Legrand O, Lorut C, Rio B, Marie JP, Huchon G.

Leukemia. 2008 Jul;22(7):1361-7. doi: 10.1038/leu.2008.100. Epub 2008 Apr 24.

PMID:
18432262
50.

Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML).

Tang R, Faussat AM, Perrot JY, Marjanovic Z, Cohen S, Storme T, Morjani H, Legrand O, Marie JP.

BMC Cancer. 2008 Feb 13;8:51. doi: 10.1186/1471-2407-8-51.

Supplemental Content

Loading ...
Support Center